Background: Magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) show promise for molecular cancer imaging. We evaluated 3T MRI, FDG PET/CT, and ultrasound images for asymptomatic women with an abnormal screening mammogram. Methods: The Institutional Review Board of Kaohsiung Veterans General Hospital (Kaohsiung, Taiwan) approved the study. Patients provided written informed consent. A total of 11,865 screening mammograms of 118,65 women were performed at our facility between January 2011 and December 2012. Fifty-three asymptomatic women (mean age, 53.3 years) whose screening mammograms had a Breast Imaging Reporting and Data System (BI-RADS) category of 4 or 5 were ultimately enrolled in this study. Breast 3T MRI, FDG PET/CT, and breast ultrasound were performed before biopsy. All imaging modalities were compared by lesion-by-lesion analyses. Results: Fifty-nine breast lesions (28 malignant and 31 benign lesions) from 53 women were analyzed. The sensitivity, specificity, and accuracy for 28 breast cancers were 96%, 77%, and 86%, respectively, for breast 3T MRI; 50%, 100%, and 76%, respectively, for FDG PET,CT; and 61%, 87%, and 74%, respectively, for breast ultrasound. One 0.8-cm invasive breast cancer was missed by the screening mammogram, but detected by breast 3T MRI and FDG PET/CT. The sensitivity for detecting breast cancer was significantly higher with MRI than with PET/CT or ultrasound (for all, p < 0.01). The specificity for detecting breast cancer was significantly higher for PET/CT than for breast MRI ( p ¼ 0.02). The sensitivity exhibited by 3T breast MRI and FDG PET/CT for 16 noninvasive breast cancers was 94% and 25%, respectively. Conclusion: On screening mammograms, breast 3T MRI showed higher sensitivity but less specificity than FDG PET/CT for detecting asymptomatic breast cancers.
Introduction
Physicians have used conventional breast imaging tests such as mammograms and breast ultrasound for diagnosing patients with a lump in the breast. Early breast cancers are usually not palpable and show only subtle findings on a mammogram. 1e3 Mammograms are widely used for breast cancer screening, but overdiagnosis and underdiagnosis can occur in screening tests. 1e3 Women assessed by the Breast Imaging Reporting and Data System (BI-RADS) as category 4 or 5 on a screening mammogram are usually recommended for a definitive diagnosis with a biopsy. Approximately 10 women per 1000 screened women require further breast biopsy because of the suspicion of breast cancer. 4 The biopsy recommendation rates, the breast cancer detection rates, and the ratio of malignant to benign biopsies are correlated with a radiologist's experience in interpreting screening mammograms. 5 The average percentage of biopsy-proven breast cancers among screened women with a BI-RADS category of 4 or 5 was reportedly 34%. 6 A recent study has shown an increasing trend in the biopsy rate and a decrease in the percentage of malignant biopsy results for women receiving screening mammogram. 5 A false-positive screening mammogram is associated with a heightened breast cancer concern, uncertainty regarding the benefits of screening, and a belief that abnormal test results do not indicate that women have cancer. 7 Additional or alternative imaging tests after an abnormal screening mammogram are of particular importance to screened women, breast surgeons, and breast radiologists. Women who hesitate to have a biopsy may seek second opinions from other breast specialists or undergo alternative breast imaging tests such as breast magnetic resonance imaging (MRI), fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), and breast ultrasound. Positron emission tomography or FDG PET/CT has an important role in breast cancer staging, and is used to predict breast cancer recurrence and to restage breast cancer after therapy. 8 An MRI scan with a dedicated breast surface coil is very sensitive in its capacity to detect clinically and mammographically occult breast cancer in the contralateral breast in women with recently diagnosed breast cancer. 9 Magnetic resonance imaging is the most effective tool for screening breast disease in women at high risk. 10 Recent research has found that 3T MRI yields a higher breast cancer detection rate and positive predictive value than 1.5T MRI for screening women. 11 However, MRI may also miss certain early calcified cancers that are commonly visible on a mammogram, and it has a higher false-positive rate. 12 The newly developed PET/ MRI fusion imaging modality is another investigative tool that could provide even further enhanced diagnostic capability in the future. We investigated the clinical applications of breast 3T MRI, FDG PET/CT, and breast ultrasound for predicting breast cancer in women with abnormal mammograms.
Methods

Participants
This prospective study was compliant with the Health Insurance Portability and Accountability Act (HIPAA) and approved by the Institutional Review Board (IRB) of Kaohsiung Veterans General Hospital in Kaohsiung, Taiwan (IRB number VGHKS11-CT4-13). All research participants provided written informed consent. A total of 11,865 screening mammograms from 11,865 women were obtained at our facility between January 2011 and December 2012. Among these women, 1209 (10.2%) women had screen-positive results and were in BI-RADS category 4 or 5. 13 They were thereafter invited to participate in this study. Fifty-five women finished the complete imaging tests. However, two women who ultimately refused to undergo biopsy were excluded. The remaining 53 women (mean age, 53.3 years; age range, 40e64 years) underwent breast 3T MRI, FDG PET/CT, and breast ultrasound before biopsy ( Figs. 1 and 2 ). Their final histopathology findings were compared with the results of all imaging tests.
Full field digital mammogram
Asymptomatic women who had a final BI-RADS category of 4 or 5 on the mammogram were recommended to undergo biopsies for positive screening results. These women each had standard full field digital mammogram (Selenia Model; Hologic Inc., Bedford, MA, USA), which consisted of the mediolateral oblique (MLO) view and the craniocaudal (CC) view. Furthermore, other diagnostic mammograms with additional views were performed for these equivocal mammographic findings.
3T MRI
With the patient prone, all MRI images were acquired with a 3T scanner (Skyra; Siemens, Erlangen, Germany) that used a 16-channel bilateral breast coil. After axial localizer scanning, morphological studies and dynamic studies were performed.
The dynamic study was performed using T1-weighted fast low angle shot (FLASH) three-dimensional (3D) MRI with fat-suppressed sequence and the following parameters: repetition time/echo time (TR/TE), 4.7 /1.7 ms; flip angle, 10 ; iPAT acceleration factor with GRAPPA, 2; matrix, 384 Â 384; field of view, 320 mm Â 320 mm; slice thickness, 1 mm; and voxel size, 0.8 mm Â 0.8 mm Â 1 mm. The temporal acquisition (range, < 60 seconds) was performed according to the volume of the breasts and the field of view. Dynamic contrastenhanced MRI was started simultaneously with the injection of 1.0M gadobutrol (Gadovist; Schering AG, Berlin-Wedding, Germany) at a dose of 0.1 mmol/kg body weight by a power injector at a rate of 2e3 mL/s and followed by a 10-mL saline flush. The 3D sequence was acquired before the injection and six times continuously after the injection of the contrast agent. The acquired images were analyzed at a workstation (Syngo; Siemens) for post processing with commercial software (Syngo).
FDG PET/CT imaging
Women who participated in this study fasted for at least 6 hours before undergoing FDG PET/CT imaging. Their serum glucose levels were checked before the injection of the 18 F-FDG radioactive tracer. All women had blood glucose levels < 150 mg/dL at the time of the tracer injection. Each woman received 370e555 MBq (10e15 mCi) of 18 F-FDG, based on her body weight (0.19 mCi/kg). After injecting the radioactive tracer, the woman rested for~60 minutes. Whole body FDG PET/CT (Discovery ST-16; GE Healthcare, Milwaukee, WI) was performed from the head to the upper thigh with the woman supine.
Before PET scanning, CT scanning was performed with the following parameters: 0.6 seconds per rotation, 120 kV, 100 mA, and 3.75-mm thick slices. After completing a plain CT, PET images of the same areas were acquired in the twodimensional mode for 4 minutes per bed position. Attenuation-corrected PET images were reconstructed using an ordered subset expectation maximization iterative reconstructed algorithm. The FDG PET/CT images were reconstructed by the Xeleris functional imaging workstation (GE Healthcare). A standardized uptake value (SUV) was determined semi-automatically on the Xeleris workstation.
Breast ultrasound
Before a woman underwent a biopsy, a breast ultrasound was performed by one of four ultrasound technologists who had 3e15 years of experience. The ultrasound technologists performed the procedure using high-resolution (12-MHz linear-array transducer) and ultrasound equipment Logiq-9 (GE Healthcare).
Imaging interpretation
All mammograms, MRIs, and ultrasounds were prospectively evaluated by one of six scheduled breast radiologists who had 3e20 years of experience. The radiology reports and breast density were classified according to the BI-RADS categories. 13, 14 In addition, the PET/CT results were interpreted by one of two qualified nuclear medicine physicians.
Pathohistology study
Stereotactic biopsy was performed utilizing a handheld 10-gauge vacuum-assisted biopsy system (Vacora System; Bard Biopsy Systems, Tempe, AZ, USA). Ultrasound-guided biopsy was performed by a freehand technique with a Magnum 14G automatic biopsy gun (Bard Biopsy Systems). All participants with biopsy-proven breast malignancy underwent a definitive surgical treatment in compliance with the standard institutional protocol. The pathologic tumor stages after therapeutic surgery were determined according to the recently revised seventh edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 15 
Statistical analysis
Sensitivity, specificity, and the positive and negative predictive values were employed to describe the diagnostic value of breast MRI, PET-CT, and breast ultrasound in evaluating mammographically detected questionable lesions. The detected lesions on breast 3T MRI, breast ultrasound, and FDGPET/ CT were calculated for statistical analysis. McNemar's test for correlated proportions was utilized to assess the significance for sensitivity, specificity, and accuracy. Statistical calculations were performed using SPSS software (SPSS for Windows, version 19; SPSS Inc., Chicago, IL, USA). Findings with p < 0.05 were considered statistically significant.
Results
The Table 1 ). The maximal tumor size of the invasive breast cancer ranged 0.1e3.3 cm (mean, 1.2 cm). One woman had both IDC (0.8 cm) and DCIS in her ipsilateral breast; the IDC was missed by the screening mammogram but detected by breast 3T MRI and by FDG PET/CT.
The major mammographic finding of 59 lesions was calcification [42 (71%) women]. Among 16 noninvasive breast cancers, the tumors presented with calcification (n ¼ 14), as a mass (n ¼ 1), or with architectural distortion (n ¼ 1). Among Table 1 The imaging data of 59 breast lesions.
BI-RADS category
Invasive breast cancer (n ¼ 12) Among 59 breast lesions, 14 lesions were FDG-avid and 45 lesions were nonFDG-avid. The FDG PET/CT scans, which were performed with the women supine, depicted 10 (83%) of 12 invasive breast cancers and four (25%) of 16 noninvasive breast cancers. The SUV in breast cancers ranged from undetectable levels to 8.6. The maximum SUV (SUV max ) of 14 PET/CT-detected breast cancers ranged 1.7e8.6 (mean value, 3.1 ± 1.8). No benign lesion showed a positive finding on PET/CT. Breast cancers that were missed by FDG PET/CT imaging were small invasive breast cancer (size, < 0.5 cm) or noninvasive breast cancers. The mean size of invasive breast cancer on FDG PET/CT was 1.3 cm (range, 0.8e2.7 cm).
The sensitivity, specificity, and accuracy of the imaging tools in analyzing 59 breast lesions were measured and compared ( Table 2 ). The sensitivity of breast MRI in detecting breast cancers was significantly higher than the sensitivity of FDG PET/CT ( p < 0.01) and breast ultrasound ( p < 0.01). The specificity of FDG PET/CT for breast cancer diagnosis was significantly higher than the specificity of breast MRI ( p ¼ 0.02). The accuracy in differentiating benign lesions from malignant breast lesions was significantly higher in breast 3T MRI than in FDG PET/CT ( p < 0.01) or breast ultrasound ( p < 0.01). There were no significant differences in communication between FDG PET/CT and breast ultrasound. Breast MRI had significantly higher diagnostic accuracy than FDG PET/CT and ultrasound (for all, p < 0.01).
Among 12 patients with invasive breast malignancies, 11 patients had subsequent surgery for the breast tumor and one patient refused any treatment. Only one patient had axillary lymph node metastases on surgery. The T (i.e., tumor size) stage according to the pathological staging (pTNM) was 1a (n ¼ 3), 1b (n ¼ 3), 1c (n ¼ 4), and T2 (n ¼ 1), based on the seventh edition of the AJCC Cancer Staging Manual. Table 3 shows the preoperative estimation of the tumor size by different imaging modalities. A higher T stage was incorrectly assigned by breast 3T MRI for six (55%) invasive breast cancers, by FDG PET/CT for three (28%) invasive breast cancers, by ultrasound for two (17%) invasive breast cancers, and by mammogram for four (36%) invasive breast cancers. An underestimated T stage was assigned by FDG PET/CT in 17% of patients, by ultrasound in 28% of patients, by mammogram in 28% of patients, and by MRI in 0% of patients.
Discussion
A mammogram has limitations in its capacity to detect breast cancer in dense and heterogeneously dense breasts. 16 In fact, mammograms with a BI-RAD category of 4 or 5 are clinical puzzles because of the wide range of malignancy possibilities (2e95%). 17 The positive predictive values for a biopsy of calcification detected by a screening mammogram are generally low because of the greater diagnostic uncertainty. 17 Breast MRI and FDG PET/CT are also commonly used for diagnosis and staging breast cancer. We found that breast 3T MRI had a higher sensitivity and accuracy than FDG PET/CT and breast ultrasound. We also presented the pros and cons of PET/CT and 3T breast MRI separately. Combining mammography, ultrasound, and MRI provide increased sensitivity and reliability, compared to using an individual imaging test alone. 16 This study indicated that, because of their unique diagnostic methodologies, breast 3T MRI and PET/CT could be helpful for evaluating asymptomatic women with an abnormal mammogram. Future PET/MR hybrid systems may provide additional clinical applications for breast cancer patients.
A previous investigation reported that 48% of DCIS could be missed by mammogram but diagnosed by MRI alone. 18 We have noted a scarcity of lesion-based studies using mammograms, breast ultrasound, FDG PET/CT, and breast 3T MRI for breast lesions. The advantages of using high-cost FDG PET/CT or PET/MRI for more effective assessment of potentially troubling breast lesions remain unclear. We found that FDG PET/CT could find 50% of screening-detected breast The benefits of breast 3T MRI include increased signal-tonoise ratio, higher temporal and spatial resolution, and shorter MRI scanning time. The common disadvantages of breast MRI are the high cost and high false-positive rates. 19 Dynamic contrast-enhanced MRI is commonly employed to explore the angiogenesis and vessel permeability of questionable lesions in the breast. 20 Except for lesions in which a malignancy was highly suspected on the mammogram, breast lesions that show no enhanced areas may be safely followed in view of the minute possibility of breast cancer. 21 A breast screening study 18 showed 1.5T MRI had good results for DCIS with a high nuclear grade. The diagnostic pitfall of MRI could occur as the result of nonenhancing early breast cancerdin particular, low-grade DCIS could be missed. 18 A negative MRI also indicated a relatively low risk for BI-RADS category 4 or 5 mammographic lesions. 18 Fluorodeoxyglucose PET/CT can be an effective tool in detecting distant metastases in patients with breast cancer. 22 However, the utility of FDG PET/CT in assessing a primary breast tumor is somewhat uncertain. Furthermore, the problem of radiation exposure and the higher expense of FDG PET versus other modalities continue to be noteworthy. Only small-scale studies with limited numbers of study participants have been conducted to compare the performance and efficacy between FDG PET/CT, mammogram, breast ultrasound, and breast MRI. Motion in the chest wall during patient respiration in the supine position can cause breathing artifacts during FDG PET/CT scanning. Previous research using FDG PET reported a lower detection rate of small breast cancer (size, < 1 cm). 23 In this study, the size of invasive breast cancer ranged 0.1e3.3 cm. The FDG PET/CT test was more sensitive in detecting invasive breast cancers (10/12, 83.3%) than in detecting noninvasive breast cancers (4/16, 25%). Approximately 58% (7/12) of invasive cancers in this study were < 1 cm, which demonstrated that FDGPET/CT can also detect small invasive breast cancers. Furthermore, FDG PET/CT showed different diagnostic results between invasive and noninvasive breast cancer because noninvasive breast cancers often presented as noneFDG-avid.
Ultrasound imaging showed a higher sensitivity for invasive breast cancer (9/12, 75%) than for noninvasive breast cancer (8/ 16, 50%) . Our study demonstrated a relatively low detection rate of breast ultrasound. Invasive breast cancers presenting with architectural distortion or calcifications were difficult to identify by ultrasound. Breast ultrasound in this study was administered by ultrasonographers. This is of some consequence because a previous study showed a lower procedural accuracy in the groups whose ultrasounds were performed by sonographers alone, compared to ultrasonographers and radiologists. 24 One study shows that the IDC size could be underestimated by ultrasound, but there is no similar estimation issue with mammogram, and MRI seems to overestimate the IDC size in comparison to the pathology results. 25 In our MRI study, 55% of IDCs were overestimated but none of them was underestimated. We suspect the overestimation by MRI may be related to contrast enhancement that occurs with the combinations of invasive cancers, noninvasive breast cancers, and adjacent tumor-induced desmoplastic reaction.
The limitations of this study include the relatively small sample size in the preliminary lesion-by-lesion multimodality comparisons. Because of the high cost and radiation exposure to patients, we could not establish a large-scale lesion-based prospective study that incorporated both PET/CT and MRI. We selected women with BI-RADS category 4 or 5 mammographic lesions as our "target women" because this category of patient has a higher-than-average probability of malignancy. There is a need for additional PET/MRI imaging studies to investigate the clinical application of PET and MRI. 26 From our preliminary study, we demonstrated the advantages and disadvantages of combined imaging information from PET and MRI for diagnosing breast cancers. Our preliminary results showed that breast 3T MRI has higher sensitivity and PET/CT has higher specificity for predicting breast cancer in asymptomatic women with an abnormal mammogram.
